Episodic Migraine Clinical Trials

75 clinical trials for Episodic Migraine across international registries, including 26 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine — RECRUITING · PHASE3
• A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults — RECRUITING · PHASE2
• Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine — RECRUITING
• A Study of Eptinezumab in Pediatric Participants With Episodic Migraine — RECRUITING · PHASE3
• Prophylactic Treatment With Atorvastatin for Episodic Migraine. — RECRUITING · PHASE2
• Chiropractic Care for Episodic Migraine — RECRUITING · NA
• A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine — RECRUITING · PHASE3
• Efficacy of Nerve Blocks for Episodic Migraine — RECRUITING · PHASE2
• i-NEED: NEw migrainE Drugs Database — RECRUITING
• Efficacy of Gou-Teng-San (GTS) in Patients With Episodic Migraine — RECRUITING · PHASE3
• A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE ESCALATION AND DOSE FINDING PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IPN10200 IN THE PREVENTION OF EPISODIC OR CHRONIC MIGRAINE IN ADULTS (MERANTI) — RECRUITING · PHASE2
• Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine — RECRUITING
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, CLINICAL TRIAL WITH EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF XEOMIN® INJECTIONS FOR THE PREVENTION OF EPISODIC MIGRAINE — RECRUITING · PHASE3
• Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine — RECRUITING
• CGRP Inhibition, Autonomic Function, and Migraine — RECRUITING
• Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP Quantification — RECRUITING
• Biochemical Profiling of Migraine Patients — RECRUITING
• Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments — RECRUITING
• Searching for Novel Biological Phenotypes in Migraine Patients Resistant to Treatments — RECRUITING
• A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, PARALLEL-GROUP STUDY WITH EXTENSION PHASE TO EVALUATE THE EFFICACY AND SAFETY OF DYSPORT® FOR THE PREVENTION OF EPISODIC MIGRAINE IN ADULT PARTICIPANTS — RECRUITING · PHASE3
• INTERVENTIONAL, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS (IV) EPTINEZUMAB IN PAEDIATRIC PATIENTS (6 TO 17 YEARS) FOR THE PREVENTIVE TREATMENT OF EPISODIC MIGRAINE — RECRUITING
• A PHASE 3, MULTICENTER, 12-WEEK, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ATOGEPANT FOR THE PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN PEDIATRIC SUBJECTS 6 TO 17 YEARS OF AGE — RECRUITING · PHASE3
• LONG TERM, OPEN LABEL (DOSE BLINDED), EXTENSION STUDY OF EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH CHRONIC OR EPISODIC MIGRAINE — RECRUITING
• RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF FREMANEZUMAB IN PATIENTS (6 TO 17 YEARS) WITH EPISODIC MIGRAINE — RECRUITING
• A MULTICENTER, OPEN-LABEL STUDY EVALUATING LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF MONTHLY SUBCUTANEOUS ADMINISTRATION OF FREMANEZUMAB FOR THE PREVENTIVE TREATMENT OF EPISODIC AND CHRONIC MIGRAINE IN PEDIATRIC PATIENTS 6 TO 17 YEARS OF AGE — RECRUITING
• "A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERENUMAB IN CHILDREN (6 TO < 12 YEARS) AND ADOLESCENTS (12 TO < 18 YEARS) WITH EPISODIC MIGRAINE (OASIS PEDIATRIC [EM])." — RECRUITING · PHASE3
• A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of episodic migraine (MINT-E) — TERMINATED · PHASE3
• A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults — ACTIVE_NOT_RECRUITING · PHASE3
• Neurofeedback for Episodic Migraine — NOT_YET_RECRUITING · NA
• Using Virtual Reality to Teach Mindfulness to People With Migraine — NOT_YET_RECRUITING · NA
• OmaMig Pilot: An open-label, phase IIa, single arm pilot study evaluating the potential clinical benefit and safety of omalizumab in adults with episodic migraine. — NOT_YET_RECRUITING · PHASE2
• A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants — TERMINATED · PHASE3
• A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine — ACTIVE_NOT_RECRUITING · PHASE3
• A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine — COMPLETED · PHASE3
• Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine — TERMINATED · PHASE3
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]) — TERMINATED · PHASE3
• Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention — COMPLETED · PHASE4
• A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine — COMPLETED · PHASE3
• Study of Two Digital Therapeutics for the Prevention of Episodic Migraine — COMPLETED · NA
• Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine — COMPLETED · NA
• Occipital Blocks for Acute Migraine — COMPLETED · PHASE3
• Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C) — COMPLETED · PHASE3
• Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine — COMPLETED · PHASE4
• Mi-Helper Transnasal Cooling for Acute Treatment of Migraine — COMPLETED · NA
• A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine — COMPLETED · PHASE4
• Effectiveness of Multimodal Physical Therapy in Migraine — OTHER · NA
• HD-EEG Connectivity Changes in Migraine Patients Undergoing Treatment With Anti-CGRP mAbs — OTHER
• Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients — COMPLETED · PHASE4
• The Effects of Vitamin D Plus Omega-3 Polyunsaturated Fatty Acids in Patients With Episodic Migraine — OTHER · NA
• Transnasal Cooling for Migraine — TERMINATED · NA

Refine this search